Technical Analysis for 0L35 - Sarepta Therapeutics Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 130.19 | 1.35% | 1.74 |
Earnings due: Apr 30
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
MACD Bullish Signal Line Cross | Bullish | 0.00% | |
New Uptrend | Bullish | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Multiple of Ten Bullish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
180 Bullish Setup | Bullish Swing Setup | 1.35% | |
Expansion Breakout | Bullish Swing Setup | 1.35% | |
Wide Bands | Range Expansion | 1.35% | |
Gapped Up | Strength | 1.35% |
Alert | Time |
---|---|
Down 1% | about 16 hours ago |
Possible Inside Day | about 16 hours ago |
Possible Pocket Pivot | 5 days ago |
5x Volume Pace | 5 days ago |
Possible Inside Day | 5 days ago |
Get this analysis on your stocks daily!
Sarepta Therapeutics Inc. Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; and AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program that is under Phase 1/2a clinical trial; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Selecta Biosciences; Hansa Biopharma; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Classification
Keywords: Biopharmaceutical Rare Diseases Gene Therapy Orphan Drugs Muscular Dystrophy Duchenne Muscular Dystrophy
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 159.7651 |
52 Week Low | 55.68 |
Average Volume | 1,061 |
200-Day Moving Average | 114.11 |
50-Day Moving Average | 99.53 |
20-Day Moving Average | 115.92 |
10-Day Moving Average | 119.89 |
Average True Range | 3.92 |
RSI (14) | 70.67 |
ADX | 25.39 |
+DI | 52.43 |
-DI | 24.34 |
Chandelier Exit (Long, 3 ATRs) | 118.42 |
Chandelier Exit (Short, 3 ATRs) | 99.77 |
Upper Bollinger Bands | 137.77 |
Lower Bollinger Band | 94.08 |
Percent B (%b) | 0.83 |
BandWidth | 37.69 |
MACD Line | 7.01 |
MACD Signal Line | 6.75 |
MACD Histogram | 0.2543 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 135.12 | ||||
Resistance 3 (R3) | 134.57 | 132.38 | 134.30 | ||
Resistance 2 (R2) | 132.38 | 131.12 | 132.65 | 134.02 | |
Resistance 1 (R1) | 131.28 | 130.35 | 131.83 | 131.83 | 133.75 |
Pivot Point | 129.09 | 129.09 | 129.36 | 129.36 | 129.09 |
Support 1 (S1) | 127.99 | 127.83 | 128.54 | 128.54 | 126.62 |
Support 2 (S2) | 125.80 | 127.05 | 126.07 | 126.35 | |
Support 3 (S3) | 124.70 | 125.80 | 126.07 | ||
Support 4 (S4) | 125.25 |